Product
Supplier
Encyclopedia
Inquiry
Home > Specialty Chemicals > Efpeglenatide zjl
Efpeglenatide zjl buy - large image1
Efpeglenatide zjl buy - image1

Efpeglenatide zjl

ISO

Unit Price:

$1/MT EXW

Get Latest Price
CAS No.:

1296200-77-5

Grade:

Chemical Grade

Content:

98%

Brand:

Dideu

Packaging:

1g/bag

Price valid (until):

2026-12-17

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

  • Product Description

  • Seller Information

  • Description

      Need COA AND CURRENT PRICE ? Please contact 1010@dideu.com

     Efpeglenatide is a GLP-1 receptor agonist under development for the treatment of type 2 diabetes and obesity and reducing the risk of cardiovascular incidents in people with these conditions.

    ECHEMI Editorial Reference

    Efpeglenatide (CAS No. 1296200-77-5) is a long-acting GLP-1 receptor agonist and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Efpeglenatide is characterized by its modified peptide structure and long-acting properties. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.

    Certificates

    Basic Info
    Product Name:

    Efpeglenatide

    CAS No.:

    1296200-77-5

    Categories:

    Research
    Class:

    GLP-1 receptor agonist (exendin-based, long-acting via Fc fusion + pegylation)

    Status:

    Investigational — Phase 3 completed, development discontinued (Sanofi returned rights 2021)

    Mechanism:

    A long-acting GLP-1 receptor agonist based on a modified exendin-4 peptide conjugated to a small Fc fragment with polyethylene glycol (PEG) modification. The combination of Fc fusion and pegylation extends the half-life to ~5 days, allowing once-weekly dosing. Activates GLP-1R to improve insulin sensitivity, reduce blood glucose, and decrease body weight.

    EC50 (GLP1R Ki):

    ~0.1 nM (approximate, exendin-based)

    Source:

    MCE: Efpeglenatide (CAS 1296200-77-5); AbMole product data sheet.

    Clinical Development:

    NCT03354457

    References
    PubChem:

    PubChem

    Disclaimer:

    Efpeglenatide is NOT FDA-approved. Phase 3 development was completed but the program was discontinued after Sanofi returned rights to Hanmi in 2021. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

    Location:

    https://www.dideu.com/en/

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    7

    Total Annual Revenue:

    Above $100 million

    Total Employees:

    Above 1000

    Year of Establishment:

    2016

    Certifications:

    ISO Certificate,REACH

    Company Profile
    ">Company Profile
  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.